Hem › Burkitts lymfom › New York › New York City

Kliniska studier för Burkitts lymfom i New York City, NY

13 studier för Burkitts lymfom söker deltagare vid platser i och runt New York City (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.

Officiell studietext (engelska)

Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

RekryterarFas 3

Memorial Sloan Kettering Cancer Center, New York

Ålder 1 och äldre · Alla kön · Uppdaterad 5 okt. 2026 · NCT07223021

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RekryterarFas 2

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
och 1 fler

366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

RekryterarFas 3

Mount Sinai Hospital, New York
NYP/Weill Cornell Medical Center, New York

Ålder 18 till 39 · Alla kön · Uppdaterad 2 okt. 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RekryterarFas 2

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Memorial Sloan Kettering Cancer Center, New York
NYP/Weill Cornell Medical Center, New York

365 Days · Alla kön · Uppdaterad 25 sep. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

RekryterarFas 3

David H. Koch Center for Cancer Care, New York

Ålder 18 och äldre · Alla kön · Uppdaterad 21 sep. 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RekryterarFas 1/2

Memorial Sloan Kettering Cancer Center ( Site 1010), New York

6 Months – 25 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT06395103

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

RekryterarFas 1

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RekryterarFas 2

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
NYP/Weill Cornell Medical Center, New York

Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RekryterarFas 3

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Mount Sinai Hospital, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
och 2 fler

365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085